Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine combo aims to supercharge immune attack on aggressive breast cancer

NCT ID NCT05325632

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy and targeted therapy can help people with HER2-positive breast cancer. About 53 participants will receive the vaccine alongside standard drugs before surgery. The main goal is to see if this combination leads to no cancer remaining at the time of surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.